Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

Victoria J SinibaldiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USAAbstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent dat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Victoria J Sinibaldi
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/461e3f974a96437bb4f7c96c98c0d964
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:461e3f974a96437bb4f7c96c98c0d964
record_format dspace
spelling oai:doaj.org-article:461e3f974a96437bb4f7c96c98c0d9642021-12-02T08:30:40ZDocetaxel treatment in the elderly patient with hormone refractory prostate cancer1178-1998https://doaj.org/article/461e3f974a96437bb4f7c96c98c0d9642008-01-01T00:00:00Zhttps://www.dovepress.com/docetaxel-treatment-in-the-elderly-patient-with-hormone-refractory-pro-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Victoria J SinibaldiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USAAbstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.Keywords: docetaxel, hormone refractory prostate cancer, elderly patientVictoria J SinibaldiDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 555-560 (2008)
institution DOAJ
collection DOAJ
language EN
topic Geriatrics
RC952-954.6
spellingShingle Geriatrics
RC952-954.6
Victoria J Sinibaldi
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
description Victoria J SinibaldiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USAAbstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.Keywords: docetaxel, hormone refractory prostate cancer, elderly patient
format article
author Victoria J Sinibaldi
author_facet Victoria J Sinibaldi
author_sort Victoria J Sinibaldi
title Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
title_short Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
title_full Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
title_fullStr Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
title_full_unstemmed Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
title_sort docetaxel treatment in the elderly patient with hormone refractory prostate cancer
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/461e3f974a96437bb4f7c96c98c0d964
work_keys_str_mv AT victoriajsinibaldi docetaxeltreatmentintheelderlypatientwithhormonerefractoryprostatecancer
_version_ 1718398479984754688